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Introduction 
A drug interaction occurs whenever a chemical 
substance, or another drug, modifies the pharmaco- 
logical effects of a therapeutically administered medi- 
cation. A study of 9900 general hospital in-patients 
in the U.S.A. found that 6.5% of all adverse drug 
reactions were caused by drug interactions (1) while 
an earlier study of patients in a chronic diseases 
hospital found a higher incidence of 22% (2). Asthma 
is a chronic condition which is usually treated, except 
in the mildest cases, with multiple drugs (3) and 
asthmatics are at higher risk for a number of other 
chronic conditions which may require medication, 
including hayfever, eczema, depression (4) and 
corticosteroid-induced diabetes. Asthma is fairly 
common in the elderly, who may well be receiving 
treatment for other chronic disorders such as hyper- 
tension and arthritis. Thus there is considerable 
scope for drug interactions to occur during the 
management of asthmatic patients. 
Reported interactions with medications used in the 
treatment of asthma are shown in Table 1. These 
have been obtained from published reviews (5,6), the 
manufacturers’ data sheets (7) and individual pub- 
lished reports. The table includes only potentially 
adverse interactions; some interactions may be poten- 
tially beneficial and these are described in the relevant 
sections below. 
Sympsthomimetic bronchodilators 
These act by stimulation of the &adrenergic 
receptor, and thus will be specifically antagonized by 
/I- receptor blocking agents, whose use in asthmatic 
patients is in any case contra-indicated. Concurrent 
use of theophyllines carries an increased risk of 
hypokalaemia, but at the same time gives rise to 
potentially additive bronchodilatation. The use of 
a-adrenergic antagonists (for example indoramin) 
together with sympathomimetic amines potentiates 
the bronchodilator action of the latter and this is 
therefore also a potentially useful interaction. Non- 
selective adrenergic agonists (adrenaline, ephedrine, 
and isoprenaline) interact with monoamine oxidase 
inhibitors, adrenergic neurone blockers, and tricyclic 
antidepressants; severe hypertensive reactions may 
occur. 
Bambuterol (an orally-administered prodrug of 
terbutaline) reversibly inhibits plasma cholinesterase, 
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leading to a prolongation of muscle paralysis after 
the use of suxamethonium during surgery. In general, 
interactions with p-agonists are more likely when 
these are administered orally or intravenously rather 
than by inhalation, due to the higher systemic con- 
centrations attained. The use of subcutaneous terb- 
utaline during inhalational anaesthesia, for example, 
has been associated with the development of cardiac 
arrhythmias (8). 
Theophylline and its derivatives 
A very large number of interactions have been 
reported with theophylline and its derivatives. 
Numerous agents increase the plasma levels of theo- 
phyllines, with the associated risk of toxicity; these 
include oral contraceptives, cimetidine, several 
macrolide and quinolone antibiotics, and the anti- 
depressant fluvoxamine (9). BCG and possibly influ- 
enza vaccines may also elevate theophylline levels, 
probably by inhibiting the hepatic cytochrome p-450 
enzyme system. Dietary methylxanthines (caffeine 
and theobromine in tea, coffee, chocolate, and cola 
drinks) compete with theophylline for the same meta- 
bolic pathways, prolonging its plasma half-life. 
Diuretic use has been shown to be associated with 
high serum theophylline levels (10) although this 
association is not necessarily causal. 
Hepatic enzyme induction by rifampicin and 
anti-epileptic drugs enhances the metabolism of 
theophylline, with a resulting fall in plasma 
levels. Both cigarette smoking and eating charcoal- 
grilled beef lead to enzyme induction and have 
been reported to reduce theophylline plasma 
concentrations. 
Care should be exercised if patients taking theo- 
phyllines require general anaesthesia as the risk of 
arrhythmias during halothane anaesthesia is 
increased, as is the risk of seizures occurring with 
ketamine anaesthesia. 
Corticosteroids 
Corticosteroids are also known to interact with 
a large number of other drugs. The metabolism 
of corticosteroids may be enhanced by co- 
administration of anti-epileptics, rifampicin, and 
ephedrine, leading to lower plasma levels and 
reduced physiological activity. Antacids may achieve 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































the same effect by reducing absorption of orally- 
administered steroids. Conversely, oral contracep- 
tives and the antifungal agent ketoconazole may 
increase corticosteroid plasma concentrations. The 
immunosuppressive agent cyclosporin has been used 
experimentally in the treatment of very severe 
asthma; it should be noted that concomitant admin- 
istration of corticosteroids increases the plasma 
levels of cyclosporin, which may lead to nephro- 
toxicity. Corticosteroids, P-agonists, theophyllines, 
and diuretics have additive effects in lowering 
serum potassium levels, whilst corticosteroids and 
P-agonists both have hyperglycaemic effects and may 
exacerbate pre-existing diabetes, leading to a require- 
ment for an increase in anti- diabetic medication. 
Significant drug interactions are very unlikely 
when corticosteroids are given by the inhaled route, 
due to the low plasma concentrations attained. 
Probably the most important interaction is the 
potential for additive effects with corticosteroids 
co-administered by other routes. Significant adrenal 
suppression has been described in a child receiving 
both inhaled and intranasal corticosteroids (11). The 
Scandinavian (but not the British) prescribing infor- 
mation for budesonide nasal spray refers to an effect 
of cimetidine on budesonide pharmacokinetics which 
is stated to be of minor clinical importance (12). 
It has been known for many years that corticoster- 
oid therapy can potentiate the bronchodilator 
response to sympathomimetic agents (13). This 
results from a dual effect of corticosteroids on the p- 
adrenoceptor, both up-regulating the number of 
receptors and also increasing the efficiency of the 
coupling mechanism of the receptor to the enzyme 
adenyl cyclase (14). 
Other anti-asthma medications 
There have been no reported drug interactions 
with the inhaled anticholinergic agents, ipratropium 
and oxitropium, other than the rather theoretical 
suggestion that dryness of the mouth resulting from 
anticholinergic therapy might reduce the dissolution 
of sublingual glyceryl trinitrate tablets. 
There are no known drug interactions with sodium 
cromoglycate or nedocromil sodium. The sedative 
effects of the anti-allergic agent ketotifen may be 
potentiated by co-administration of alcohol, CNS 
depressants, or other antihistamines. More seriously, 
the use of ketotifen together with oral antidiabetic 
agents carries a risk of thrombocytopaenia, and 
should be avoided. 
In v&w drug interactions 
The interactions discussed and tabulated have all 
been described in vivo; however, it should not be 
forgotten that drugs can also interact outside the 
body, for example when mixed prior to nebulization 
or infusion. There is little information on the 
compatibility of anti-asthma agents in these situ- 
ations; however, the manufacturers of Becotide 
(beclomethasone dipropionate) suspension for 
nebulization and Steri-neb Salamol (salbutamol) 
state that these should not be mixed with other 
medications, while the manufacturer of Pulmicort 
(budesonide) Respules states that these can be mixed 
with solutions of terbutaline, salbutamol, sodium 
cromoglycate, or ipratropium bromide. 
CONCLUSION 
Clearly, there is ample scope for the occurrence of 
drug interactions during the management of asthma. 
Some of these may be potentially beneficial, but the 
majority are potentially deleterious. Interactions may 
occur between more than two drugs simultaneously; 
for example, recent data suggest that coadministra- 
tion of cimetidine and ciprofloxacin leads to greater 
impairment of theophylline metabolism than either 
agent given alone (1.5). As has been pointed out, 
‘every time a physician adds to the number of drugs a 
patient is taking he may devise a novel combination 
that has a special risk hitherto unsuspected’ (16). 
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